Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von David N Springer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology, Medical University of Vienna, Wien, Austria. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Stadt Wien.
Abstract (Originalsprache)
SARS‐CoV‐2 Omicron lineages continue to emerge and evolve into new sublineages, causing infection waves throughout 2022 and 2023, which has been attributed to immune escape. We examined neutralizing antibody responses to the recently emerged SARS‐CoV‐2 JN.1 variant in comparison to ancestral D614G and Omicron BA.1, BA.2, BA.5, and XBB.1.5 variants. We tested 79 human sera from cohorts with different combinations of vaccinations and infections, including 23 individuals who had been repeatedly exposed to Omicron. Individuals with a monovalent XBB.1.5 vaccine booster or XBB.1.5 breakthrough infection had robust antibody levels against all variants tested; however, JN.1 evaded antibodies in individuals after single Omicron BA.1, BA.2 or BA.5 breakthrough infections. Moreover, in the non‐vaccinated cohort, serum antibodies demonstrated almost no cross‐neutralization activities against D614G, XBB.1.5 and JN.1. after infections with earlier Omicron variants. These findings show that SARS‐CoV‐2‐immunity is heterogeneous, depending on different combinations of vaccinations and infections, and emphasize the importance of considering different immune‐backgrounds when evaluating novel variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Virology, Medical University of Vienna, Wien, Austria.
- Independent Researcher, Völkermarkt, Austria.
- Independent Researcher, Ramsau am Dachstein, Austria.
ORCID-Profile: Jeremy V Camp, Lukas Weseslindtner, Karin Stiasny, Judith H Aberle
Förderung
- Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Stadt Wien
Zitieren
APA
Springer, D. N., Camp, J. V., Aberle, S. W., Deutsch, J., Lammel, O., Weseslindtner, L., Stiasny, K., & Aberle, J. H. (2024). Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.29801
Vancouver
Springer DN, Camp JV, Aberle SW, Deutsch J, Lammel O, Weseslindtner L, et al. Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection. Journal of Medical Virology. 2024. doi:10.1002/jmv.29801
BibTeX
@article{Springer2024,
author = {Springer, David N and Camp, Jeremy V and Aberle, Stephan W and Deutsch, Josef and Lammel, Oliver and Weseslindtner, Lukas and Stiasny, Karin and Aberle, Judith H},
title = {Neutralization of SARS‐CoV‐2 Omicron XBB.1.5 and JN.1 variants after COVID‐19 booster‐vaccination and infection},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29801}
}
EUVIMED